VERTEX PHARMACEUTICALS INC / MA OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax
VERTEX PHARMACEUTICALS INC / MA (VRTX) reported OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax of $0 for the 12-month period ending 2019-12-31, per its 10-K filed 2020-02-13.
Discontinued › Expense Statement › Income Tax
us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax · last filed 2020-02-13
- VERTEX PHARMACEUTICALS INC / MA oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment, tax for the quarter ending 2018-06-30 was $0.00, a 100.00% decline year-over-year.
- VERTEX PHARMACEUTICALS INC / MA oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment, tax for the quarter ending 2018-03-31 was $0.00, a 100.00% decline year-over-year.
- VERTEX PHARMACEUTICALS INC / MA oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment, tax for the quarter ending 2017-12-31 was -$2.70M.
- VERTEX PHARMACEUTICALS INC / MA oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment, tax for the quarter ending 2017-09-30 was $0.00.
- VERTEX PHARMACEUTICALS INC / MA oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment, tax for fiscal 2019 was $0.00.
- VERTEX PHARMACEUTICALS INC / MA oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment, tax for fiscal 2018 was $0.00.
- VERTEX PHARMACEUTICALS INC / MA oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment, tax for fiscal 2017 was -$2.70M.
- VERTEX PHARMACEUTICALS INC / MA oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment, tax for fiscal 2016 was -$3.80M.
| Period end | OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax 3 month | OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax 3 month as first filed | OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax 6 month | OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax 9 month | OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax 12 month |
|---|---|---|---|---|---|
| 2019-12-31 | $0.00 10-K · filed 2020-02-13 | ||||
| 2018-12-31 | $0.00 10-K · filed 2020-02-13 | ||||
| 2018-06-30 | $0.00 10-Q · filed 2018-07-26 | $0.00 10-Q · filed 2018-07-26 | -$2.70M derived: sum of 3 quarters · filed 2020-02-13 | -$2.70M derived: sum of 4 quarters · filed 2020-02-13 | |
| 2018-03-31 | $0.00 10-Q · filed 2018-04-27 | -$2.70M derived: sum of 2 quarters · filed 2020-02-13 | -$2.70M derived: sum of 3 quarters · filed 2020-02-13 | -$1.70M derived: sum of 4 quarters · filed 2020-02-13 | |
| 2017-12-31 | -$2.70M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-13 | -$2.70M derived: sum of 2 quarters · filed 2020-02-13 | -$1.70M derived: sum of 3 quarters · filed 2020-02-13 | -$2.70M 10-K · filed 2020-02-13 | |
| 2017-09-30 | $0.00 10-Q · filed 2017-10-30 | $1.00M derived: sum of 2 quarters · filed 2018-07-26 | $0.00 10-Q · filed 2017-10-30 | -$1.80M derived: sum of 4 quarters · filed 2019-02-13 | |
| 2017-06-30 | $1.00M 10-Q · filed 2018-07-26 | -$1.00M 10-Q · filed 2017-07-28 | $0.00 10-Q · filed 2018-07-26 | -$1.80M derived: sum of 3 quarters · filed 2019-02-13 | -$1.80M derived: sum of 4 quarters · filed 2019-02-13 |
| 2017-03-31 | $1.00M 10-Q · filed 2018-04-27 | -$2.80M derived: sum of 2 quarters · filed 2019-02-13 | -$2.80M derived: sum of 3 quarters · filed 2019-02-13 | -$2.80M derived: sum of 4 quarters · filed 2019-02-13 | |
| 2016-12-31 | -$3.80M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-13 | -$3.80M derived: sum of 2 quarters · filed 2019-02-13 | -$3.80M derived: sum of 3 quarters · filed 2019-02-13 | -$3.80M 10-K · filed 2019-02-13 | |
| 2016-09-30 | $0.00 10-Q · filed 2017-10-30 | $0.00 derived: sum of 2 quarters · filed 2017-10-30 | $0.00 10-Q · filed 2017-10-30 | ||
| 2016-06-30 | $0.00 10-Q · filed 2017-07-28 | $0.00 10-Q · filed 2017-07-28 | |||
| 2015-12-31 | $0.00 10-K · filed 2018-02-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |